Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synergo RITE vs BCG for NMIBC
NCT02254915Phase 3Withdrawn
- Sponsor
- Medical Enterprises Europe
- Primary completion
- Jan 2020
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Medical Enterprises Europe. Primary endpoint: Recurrence-Free Survival time at 2 years. Status: withdrawn.
Beyond the preview
Go deeper on NCT02254915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254915.